Kymera Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kymera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$62.5M, a 18.2% decline year-over-year.
  • Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$167M, a 0.01% decline year-over-year.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$147M, a 5.07% increase from 2022.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$155M, a 54.5% decline from 2021.
  • Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$100M, a 120% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$147M +$7.85M +5.07% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$155M -$54.6M -54.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$100M -$54.6M -120% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$45.6M -$4.35M -10.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$41.2M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.